Journal article
Previous Bevacizumab and Efficacy of Later Anti–Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry
M Burge, C Semira, B Lee, M Lee, S Kosmider, R Wong, J Shapiro, B Ma, AP Dean, AS Zimet, SA Steel, SW Lok, J Torres, M Eastgate, HL Wong, P Gibbs
Clinical Colorectal Cancer | CIG MEDIA GROUP, LP | Published : 2018
Abstract
The sequencing of biologic agents used in metastatic colorectal cancer can affect the outcomes. We analyzed a multicenter registry to address a question that could not be answered using current clinical trial data. We found that whether or not patients had received previous bevacizumab, the effect of epidermal growth factor receptor antibodies in later lines of therapy was maintained. Background: The FIRE-3 [5-fluorouracil, folinic acid, and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment colorectal cancer (CRC)] study reported that first-line FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab resulted in similar progression-free survival (PFS)..
View full abstractGrants
Funding Acknowledgements
The development and maintenance of the registry used in this work is supported by Roche Products, Pty, Ltd (Australia). This work would not have been possible without data analysis by Julie Johns, Gibbs Laboratory, Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research.